Bandhan Mutual Fund
When comparing, both lines start at 100. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare TRI) is not available to us as a series.
This is an IDCW (dividend) option: it pays cash out of its NAV, so returns computed from the NAV alone would understate what an investor earned. See the Growth option of the same plan for performance.
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. Shown from the Direct plan of this fund, which holds the same portfolio. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Healthcare | 10.48% | — | 143.5 |
| Cipla Limited | Healthcare | 6.38% | — | 35.1 |
| Max Healthcare Institute Limited | Healthcare | 5.81% | — | 124.3 |
| Apollo Hospitals Enterprise Limited | Healthcare | 5.64% | — | 73.1 |
| Triparty Repo TRP_010926 | — | 4.33% | — | — |
| Divi's Laboratories Limited | Healthcare | 4.28% | — | 83.0 |
| Aurobindo Pharma Limited | Healthcare | 4.14% | — | 37.5 |
| Lupin Limited | Healthcare | 3.96% | — | 13.2 |
| Shilpa Medicare Limited | Healthcare | 3.72% | — | 110.1 |
| GlaxoSmithKline Pharmaceuticals Limited | Healthcare | 3.68% | — | 43.8 |
| Dr. Reddy's Laboratories Limited | Healthcare | 3.48% | — | 150.9 |
| Torrent Pharmaceuticals Limited | Healthcare | 3.36% | — | 77.7 |
| Gland Pharma Limited | Healthcare | 3.05% | — | 34.4 |
| Zydus Lifesciences Limited | Healthcare | 2.78% | — | 32.6 |
| Narayana Hrudayalaya Limited | Healthcare | 2.59% | — | 61.9 |
| Global Health Limited | Healthcare | 2.45% | — | 74.4 |
| Syngene International Limited | Healthcare | 2.42% | — | 62.8 |
| Eris Lifesciences Limited | Healthcare | 2.35% | — | 84.5 |
| Glenmark Pharmaceuticals Limited | Healthcare | 2.24% | — | 316.1 |
| Rainbow Childrens Medicare Limited | Healthcare | 2.13% | — | 51.3 |
| Pfizer Limited | Healthcare | 1.84% | — | 23.9 |
| Ajanta Pharma Limited | Healthcare | 1.74% | — | 43.2 |
| Healthcare Global Enterprises Limited | Healthcare | 1.66% | — | 571.8 |
| Sanofi India Limited | Healthcare | 1.51% | — | 21.5 |
| Novartis India Limited | Healthcare | 1.50% | — | 49.7 |
| IPCA Laboratories Limited | Healthcare | 1.49% | — | 39.8 |
| Jubilant Pharmova Limited | Healthcare | 1.46% | — | 677.0 |
| Thyrocare Technologies Limited | Healthcare | 1.46% | — | 34.6 |
| Alivus Life Sciences Limited | Healthcare | 1.36% | — | 28.0 |
| AstraZeneca Pharma India Limited | Healthcare | 1.26% | — | 87.1 |
| Sai Life Sciences Limited | Healthcare | 1.10% | — | 89.9 |
| Orchid Pharma Limited | Healthcare | 1.08% | — | 143.5 |
| Sai Parenterals Limited | Healthcare | 0.95% | — | — |
| Medi Assist Healthcare Services Limited | Financial Services | 0.89% | — | 38.1 |
| Dr. Lal Path Labs Limited | Healthcare | 0.88% | — | 38.4 |
| Viyash Scientific Limited | Healthcare | 0.85% | — | 161.3 |
| Cash Margin - CCIL | — | 0.03% | — | — |
This is a paid feature
Comparing more months of this fund's own portfolio history is available on paid plans.
Sign inExpense ratio by month: Nov 25 0.65% · Dec 25 0.65% · Jan 26 0.67% · Feb 26 0.71% · Mar 26 0.71% · Apr 26 0.87% · May 26 0.87% · Jun 26 1.26% · Jul 26 1.20% · Aug 26 1.22% · Sep 26 1.31%
• If redeemed/switched out on or within 30 days from the date of allotment: 0.50% of the applicable NAV; • If redeemed/switched out after 30 days from date of allotment – Nil
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors.; Disclaimer: There is no assurance or guarantee that the scheme’s objectives will be realised.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
